TGFB1 and prostate cancer: The first clinical human dose-escalation study in solid cancer (e.g., melanoma, breast cancer, hepatocellular carcinoma, and prostate cancer) patients (NCT02160106) targeting TGFβRI with TEW-7197 causing downregulation of TGF-β signaling is currently completed with encouraging results.